INmune Bio, Inc. INMB 深 沪
交易中 06-25 11:44:34 美东时间
1.435
+0.085
+6.30%
华盛通- 最 高1.47
- 今 开1.36
- 成交量 879.02万股
- 最 低 1.3001
- 昨 收 1.35
- 总市值 3814.98万
- 52周最高 3.244
- 市盈率 静 --
- 换手率 33.06%
- 52周最低 1.09
- 委 比 -17.22%
- 总股本 2658.53万
- 历史最高 30.37
- 量 比 85.22
- 振 幅 12.59%
- 历史最低 1.09
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan For INmune Bio's Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ for the treatment of Reces...
今天 19:13
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio received MHRA alignment on CMC, non-clinical, and clinical strategies for Ebstrocel™ in RDEB, clearing a regulatory path for its 2026 UK MAA submission. MHRA recognized MissionEB Phase 2 data showing significant symptomatic benefits, particularly pain and pruritus, supporting chronic or intermittent therapy positioning. The agency also provided guidance on confirmatory Phase 3 trial design, evidence package, and manufacturing transitio...
06-23 12:00
Terra Innovatum Global N.V. GAAP EPS of $9.74
Terra Innovatum Global N.V. press release (NKLR): FY GAAP EPS of $9.74. Cash and cash equivalents were $102.9 million as of December 31, 2025, compared to $2.15 million as of September 30, 2025, prior...
06-16 05:43
INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase 2 Clinical Trial Of XPro In Patients With Early Alzheimer's Disease
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.Efficacy was further
06-02 20:16
电话会总结 ｜ INmune Bio(INMB)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据INmune Bio业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **净亏损表现：** 2025年归属于普通股股东的净亏损约为4,590万美元，较2024年的4,210万美元有所扩大。 **研发支出：** 2025年研发费用总计约2,070万美元，较2024年的3,320万美元显著下降，主要由于阿尔茨海默病试验相关费用减少。 **管理费用：** 2025年一般管理费用约为1,030万美元，较2024年的950万美元小幅上升。 **资产减值：** 公司在2025年对无形资产进行了1,650万美元的全额减值，原因是阿尔茨海默病试验未能达
06-02 12:30
INmune Bio shares are trading higher after the company announced that the FDA granted the fast Track designation to XPro
INmune Bio shares are trading higher after the company announced that the FDA g...
05-14 21:30
Venu Holding plans $300M Chattanooga amphitheater project
Venu Holding (VENU) on Tuesday said it entered an agreement to purchase a 15-acre site in Chattanooga, Tennessee, for the planned development of Sunset Amphitheater Chattanooga, a next-generation live...
05-12 23:18
Sidus Space prices $58.5M offering at $4.35 per share
Space and defense technology firm Sidus Space (SIDU) announced the pricing of a direct offering of ~13.4M shares at an offering price of $4.35 per share. Gross proceeds target $58.5M before placement ...
04-20 12:50
Sidus Space reports FY results
Sidus Space press release (SIDU): FY net loss was $29.5 million, compared to a net loss of $17.5 million for the same period in 2024. The increase includes a $4.5 million non-cash impairment charge re...
04-01 18:12
Inmune Bio Earnings Call Balances Progress and Risk
Inmune Bio (($INMB)) has held its Q4 earnings call. Read on for the main highli...
04-01 08:26
